Last 7 days
0.1%
Last 30 days
1.8%
Last 90 days
77.3%
Trailing 12 Months
544.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-14 | Loewen Andrea | sold | -546,181 | 172 | -3,175 | svp, global regulatory affairs |
2023-09-05 | Anand Bhaskar | sold | -68,695 | 169 | -406 | svp, chief accounting officer |
2023-08-23 | ROSE WILLIAM | gifted | - | - | -500,000 | - |
2023-08-16 | WORTLEY MICHAEL D | sold | -67,166 | 168 | -398 | chief legal officer |
2023-08-16 | Soni Manmeet Singh | sold | -295,566 | 168 | -1,755 | coo, cfo and president |
2023-08-16 | Anand Bhaskar | sold | -35,367 | 168 | -210 | svp, chief accounting officer |
2023-08-16 | Bir Dawn Carter | sold | -66,996 | 168 | -398 | chief commercial officer |
2023-08-16 | Meyer Colin John | sold | -100,569 | 168 | -596 | chief innovation officer |
2023-08-15 | WORTLEY MICHAEL D | sold | -136,415 | 169 | -807 | chief legal officer |
2023-08-15 | Meyer Colin John | sold | -362,483 | 169 | -2,144 | chief innovation officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-06 | Deep Track Capital, LP | sold off | -100 | -66,280,700 | - | -% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -69.1 | -128,896,000 | 68,334,200 | 1.98% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -34.62 | -200,519 | 551,118 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -9.67 | 39,996 | 3,129,460 | -% |
2023-08-21 | BOKF, NA | sold off | -100 | -2,273 | - | -% |
2023-08-21 | VisionPoint Advisory Group, LLC | new | - | 41,090 | 41,090 | 0.02% |
2023-08-21 | Affinity Asset Advisors, LLC | new | - | 2,967,550 | 2,967,550 | 1.04% |
2023-08-17 | Orion Portfolio Solutions, LLC | added | 0.19 | 30,064 | 273,457 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -15.37 | -514,784 | 9,588,220 | -% |
2023-08-16 | GTS SECURITIES LLC | new | - | 798,653 | 798,653 | 0.03% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Sep 19, 2023 | rose william | 8.9% | 3,182,950 | SC 13D/A | |
Aug 24, 2023 | rose william | 9.1% | 3,240,950 | SC 13D/A | |
Aug 07, 2023 | biogen inc. | 23.4% | 8,936,791 | SC 13D | |
Aug 01, 2023 | cpmg inc | 13.2% | 4,589,758 | SC 13D/A | |
Jul 31, 2023 | rose william | 9.2% | 3,240,950 | SC 13D/A | |
Jun 26, 2023 | adage capital partners gp, l.l.c. | 5.24% | 1,730,841 | SC 13G | |
May 15, 2023 | first light asset management, llc | 3.91% | 1,290,193 | SC 13G/A | |
Mar 07, 2023 | perceptive advisors llc | 6.5% | 2,083,799 | SC 13G | |
Feb 14, 2023 | first light asset management, llc | 6.79% | 2,155,552 | SC 13G/A | |
Feb 14, 2023 | point72 asset management, l.p. | 0% | 0 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 19, 2023 | 4 | Insider Trading | |
Sep 19, 2023 | SC 13D/A | 13D - Major Acquisition | |
Sep 18, 2023 | 4 | Insider Trading | |
Sep 14, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 12, 2023 | 8-K | Current Report | |
Sep 12, 2023 | DEFA14A | DEFA14A | |
Sep 07, 2023 | 4 | Insider Trading | |
Sep 05, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 05, 2023 | 144 | Notice of Insider Sale Intent | |
Aug 24, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
LLY | 512.5B | 29.5B | 3.56% | 89.32% | 78.88 | 17.36 | 1.53% | 14.16% |
JNJ | 423.3B | 97.8B | -2.65% | 0.10% | 32.43 | 4.33 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -2.13% | 26.48% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 189.8B | 77.9B | -9.16% | -24.26% | 8.84 | 2.44 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.06% | -15.06% | 23.72 | 3.25 | -4.15% | 20.34% |
MID-CAP | ||||||||
RETA | 6.5B | - | 1.75% | 544.26% | -74.04 | 4.1K | -86.94% | 71.24% |
PRGO | 4.5B | 4.6B | -11.49% | -16.32% | -66.69 | 0.98 | 6.60% | 42.04% |
SMALL-CAP | ||||||||
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -11.88% | -19.94% | 34.62 | 2.37 | 0.62% | -24.59% |
INVA | 832.3M | 244.3M | -4.13% | 4.68% | 4.22 | 3.41 | -39.50% | -4.99% |
CRON | 830.8M | 109.5M | 21.79% | -27.57% | -5.79 | 7.59 | -2.66% | -32.13% |
CGC | 480.0M | 453.3M | 110.37% | -71.69% | -0.39 | 1.06 | -16.04% | 55.90% |
ACRS | 479.1M | 31.2M | -7.77% | -52.62% | -4.55 | 15.37 | 407.54% | -26.47% |
OCUL | 269.4M | 54.6M | -13.04% | -44.44% | -2.97 | 4.93 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
29.8%
14.5%
17.8%
100%
86.5%
82.7%
Y-axis is the maximum loss one would have experienced if Reata Pharmaceuticals was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | - | - | - | 2,216,000 | 3,149,000 | 10,000,000 | 11,459,000 | 11,490,000 | 13,748,000 | 7,758,000 | 8,610,000 | 9,019,000 | 8,499,000 | 15,340,000 | 20,100,000 | 26,517,000 | 32,296,000 | 29,229,000 | 28,967,000 | 53,589,000 | 55,101,000 | 62,483,000 |
Operating Expenses | 15.4% | 376,149,000 | 325,947,000 | 280,250,000 | 273,228,000 | 267,687,000 | 265,291,000 | 256,198,000 | 240,868,000 | 231,168,000 | 222,484,000 | 235,344,000 | 365,274,000 | 356,308,000 | 344,133,000 | 311,737,000 | 158,007,000 | 145,922,000 | 138,653,000 | 130,467,000 | 123,583,000 | 113,423,000 |
S&GA Expenses | 14.7% | 159,868,000 | 139,321,000 | 109,277,000 | 107,816,000 | 106,282,000 | 103,137,000 | 99,002,000 | 87,865,000 | 80,443,000 | 75,045,000 | 75,128,000 | 77,972,000 | 73,941,000 | 69,047,000 | 58,298,000 | 43,973,000 | 37,176,000 | 36,159,000 | 32,748,000 | 30,751,000 | 29,416,000 |
R&D Expenses | 9.6% | 203,305,000 | 185,516,000 | 169,843,000 | 164,236,000 | 160,181,000 | 160,916,000 | 155,993,000 | 151,836,000 | 149,589,000 | 146,306,000 | 159,080,000 | 161,780,000 | 156,876,000 | 149,647,000 | 128,109,000 | 113,256,000 | 108,121,000 | 101,996,000 | 97,288,000 | 92,423,000 | 83,605,000 |
EBITDA | 100.0% | - | -353,122,000 | -310,796,000 | - | -303,155,000 | -298,089,000 | -290,070,000 | -270,396,000 | -264,294,000 | -255,455,000 | -255,010,000 | -373,790,000 | -347,179,000 | -317,186,000 | -278,631,000 | -118,804,000 | -110,003,000 | -105,358,000 | -74,010,000 | -67,022,000 | -50,386,000 |
EBITDA Margin | 100.0% | - | -235 | -140 | - | -30.32 | -26.01 | -25.25 | -19.67 | -34.07 | -29.67 | -28.27 | -43.98 | -22.63 | -15.78 | -10.51 | -3.68 | -3.76 | -3.64 | -1.38 | -1.22 | -0.81 |
Interest Expenses | - | 2,624,000 | - | - | - | - | - | - | - | - | 4,847,000 | 8,021,000 | 10,002,000 | 12,391,000 | 9,957,000 | 8,207,000 | 7,822,000 | 7,793,000 | 6,283,000 | 4,741,000 | 3,980,000 | 2,104,000 |
Earnings Before Taxes | 75.2% | -87,678,000 | -354,232,000 | -311,926,000 | -311,535,000 | -304,379,000 | -304,176,000 | -297,836,000 | -278,596,000 | -272,299,000 | -266,530,000 | -270,239,000 | -391,306,000 | -365,413,000 | -332,189,000 | -290,162,000 | -128,740,000 | -119,910,000 | -113,755,000 | -80,520,000 | -71,626,000 | -53,107,000 |
EBT Margin | 100.0% | - | -236 | -140 | -98.93 | -30.44 | -26.54 | -25.92 | -20.26 | -35.10 | -30.96 | -29.96 | -46.04 | -23.82 | -16.53 | -10.94 | -3.99 | -4.10 | -3.93 | -1.50 | -1.30 | -0.85 |
Net Income | 75.3% | -87,623,000 | -354,176,000 | -311,901,000 | -311,784,000 | -304,628,000 | -303,773,000 | -297,386,000 | -277,777,000 | -271,387,000 | -266,268,000 | -247,752,000 | -368,918,000 | -343,156,000 | -309,955,000 | -290,170,000 | -128,810,000 | -119,951,000 | -113,782,000 | -80,546,000 | -71,638,000 | -53,111,000 |
Net Income Margin | 100.0% | - | -236 | -140 | -99.01 | -30.46 | -26.51 | -25.88 | -20.20 | -34.98 | -30.93 | -27.47 | -43.41 | -22.37 | -15.42 | -10.94 | -3.99 | -4.10 | -3.93 | -1.50 | -1.30 | -0.85 |
Free Cashflow | 100.0% | - | -230,654,000 | -207,537,000 | -279,869,000 | -275,826,000 | -250,299,000 | -237,030,000 | -159,433,000 | -156,849,000 | -327,213,000 | -323,267,000 | -427,367,000 | -427,782,000 | -265,190,000 | -253,824,000 | -142,002,000 | -98,299,000 | -90,182,000 | -84,462,000 | -71,525,000 | -93,747,000 |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | 10.8% | 503 | 454 | 514 | 584 | 632 | 680 | 735 | 732 | 778 | 815 | 858 | 613 | 652 | 664 | 682 | 259 | 300 | 331 | 345 | 382 | 175 |
Current Assets | 20.8% | 402 | 333 | 398 | 445 | 491 | 537 | 596 | 722 | 768 | 806 | 847 | 607 | 640 | 652 | 669 | 247 | 287 | 317 | 342 | 380 | 172 |
Cash Equivalents | -42.5% | 49.00 | 85.00 | 42.00 | 32.00 | 147 | 532 | 590 | 713 | 756 | 778 | 818 | 578 | 610 | 624 | 664 | 240 | 280 | 313 | 338 | 375 | 139 |
Inventory | - | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 2.2% | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 12.00 | 7.00 | 6.00 | 5.00 | 5.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 |
Current Liabilities | 129.1% | 125 | 55.00 | 59.00 | 51.00 | 46.00 | 44.00 | 54.00 | 121 | 121 | 114 | 119 | 47.00 | 47.00 | 201 | 192 | 75.00 | 68.00 | 61.00 | 56.00 | 63.00 | 56.00 |
Long Term Debt | - | 73.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.00 | 80.00 | 79.00 | 79.00 | 79.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 156 | 155 | 75.00 | - | - | 79.00 | - | - |
Shareholder's Equity | 166.8% | 87.00 | -130 | -65.69 | 5.00 | 69.00 | 128 | 186 | 256 | 314 | 369 | 417 | 186 | 232 | 229 | 257 | - | - | - | 15.00 | 38.00 | - |
Retained Earnings | 11.5% | -1,490 | -1,683 | -1,567 | -1,482 | -1,403 | -1,329 | -1,255 | -1,170 | -1,098 | -1,025 | -958 | -892 | -827 | -759 | -710 | -523 | -483 | -449 | -420 | -394 | -363 |
Additional Paid-In Capital | 1.6% | 1,578 | 1,553 | 1,502 | 1,487 | 1,472 | 1,457 | 1,442 | 1,426 | 1,412 | 1,395 | 1,376 | 1,078 | 1,059 | 988 | 967 | 456 | 450 | 445 | 435 | 432 | 196 |
Shares Outstanding | 2.0% | 38.00 | 37.00 | - | 37.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 34.00 | 34.00 | 33.00 | 33.00 | 30.00 | 30.00 | 30.00 | 30.00 | 28.00 | 27.00 | 26.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -9.1% | -248,337 | -227,531 | -204,267 | -276,773 | -272,397 | -248,875 | -235,701 | -157,909 | -155,844 | -326,178 | -322,340 | -426,575 | -426,817 | -263,592 | -251,151 | -139,273 | -95,796 | -88,494 | -83,783 | -71,019 | -93,192 |
Share Based Compensation | 8.0% | 87,843 | 81,344 | 58,731 | 58,980 | 58,191 | 57,571 | 56,806 | 53,529 | 51,452 | 53,005 | 57,633 | 57,975 | 51,775 | 41,461 | 26,381 | 16,857 | 14,223 | 12,292 | 10,550 | 9,583 | 8,382 |
Cashflow From Investing | 125.4% | 59,417 | -233,881 | -345,164 | -405,863 | -337,399 | -1,424 | -1,329 | -1,524 | -1,005 | -1,035 | -927 | -792 | -965 | -1,598 | -2,673 | -2,729 | -2,503 | -1,688 | -679 | -505 | -554 |
Cashflow From Financing | 530.4% | 90,609 | 14,373 | 1,485 | 1,342 | 1,243 | 4,654 | 9,138 | 294,382 | 302,137 | 480,349 | 477,093 | 765,481 | 757,752 | 576,622 | 580,358 | 6,966 | 240,072 | 297,301 | 292,472 | 292,109 | 167,246 |
Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenues | ||||
Total revenues | $ 22,746 | $ 762 | $ 22,941 | $ 1,677 |
Operating cost and expenses | ||||
Cost of products sold | 846 | 0 | 846 | 0 |
Research and development | 57,120 | 39,331 | 112,597 | 79,136 |
Selling, general and administrative | 45,690 | 25,143 | 100,575 | 49,984 |
Litigation settlement | 11,000 | 11,000 | ||
Depreciation | 293 | 273 | 581 | 581 |
Total operating cost and expenses | 114,949 | 64,747 | 225,599 | 129,701 |
Other income (expense), net | 285,201 | (9,571) | 279,539 | (19,343) |
Income (loss) from operations | 192,998 | (73,556) | 76,881 | (147,367) |
Benefit from (provision for) taxes on income | 0 | 1 | 0 | (30) |
Net income (loss) | $ 192,998 | $ (73,555) | $ 76,881 | $ (147,397) |
Net income (loss) per share - basic | $ 5.12 | $ (2.02) | $ 2.06 | $ (4.04) |
Net income (loss) per share - diluted | $ 4.65 | $ (2.02) | $ 1.89 | $ (4.04) |
Weighted-average number of common shares used in net income (loss) per share - basic | 37,671,678 | 36,467,802 | 37,311,872 | 36,440,364 |
Weighted-average number of common shares used in net income (loss) per share - diluted | 41,506,900 | 36,467,802 | 40,758,929 | 36,440,364 |
Product revenues, net | ||||
Revenues | ||||
Total revenues | $ 20,038 | $ 0 | $ 20,038 | $ 0 |
License and milestone | ||||
Revenues | ||||
Total revenues | 0 | 754 | 0 | 1,648 |
Other revenue | ||||
Revenues | ||||
Total revenues | $ 2,708 | $ 8 | $ 2,903 | $ 29 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Assets | ||
Cash and cash equivalents | $ 48,843 | $ 42,312 |
Marketable debt securities | 281,371 | 345,202 |
Accounts receivable, net | 22,662 | 0 |
Prepaid expenses and other current assets | 46,031 | 10,256 |
Inventory, current | 2,942 | 0 |
Total current assets | 401,849 | 397,770 |
Property and equipment, net | 11,303 | 11,179 |
Operating lease right-of-use-assets | 78,598 | 105,258 |
Inventory, noncurrent | 10,338 | 0 |
Other assets | 499 | 284 |
Total assets | 502,587 | 514,491 |
Liabilities and stockholders' equity (deficit) | ||
Accounts payable | 19,860 | 18,706 |
Accrued direct research liabilities | 25,135 | 13,836 |
Other current liabilities | 71,991 | 24,267 |
Liability related to sale of future royalties, current | 5,650 | 0 |
Operating lease liabilities, current | 2,456 | 2,151 |
Total current liabilities | 125,093 | 58,960 |
Opearting lease liabilities, noncurrent | 90,417 | 117,313 |
Term Loan, net of debt issuance cost | 73,130 | 0 |
Liability related to sale of future royalties, non-current | 126,656 | 403,913 |
Total noncurrent liabilities | 290,203 | 521,226 |
Commitments and contingencies | ||
Stockholders' equity (deficit): | ||
Additional paid-in capital | 1,577,904 | 1,501,800 |
Accumulated deficit | (1,490,651) | (1,567,532) |
Total stockholders' equity (deficit) | 87,291 | (65,695) |
Total liabilities and stockholders' equity (deficit) | 502,587 | 514,491 |
Common Stock A | ||
Stockholders' equity (deficit): | ||
Common stock value | 33 | 32 |
Common Stock B | ||
Stockholders' equity (deficit): | ||
Common stock value | $ 5 | $ 5 |